Aggregation of activated platelets is considerably mediated by the autocrine action of thromboxane A 2 (TxA 2 ) which is formed in a prostaglandin endoperoxide H 2 synthase-1 (PGHS-1 or COX-1)-dependent manner. The activity of PGHS-1 can be stimulated by peroxides, an effect termed "peroxide tone", that renders PGHS-1 the key regulatory enzyme in the formation of TxA 2 . Activated platelets release nitric oxide ( · NO) and superoxide 
Introduction
Activation of platelets represents a key event not only in acute thrombosis but also under chronic pathophysiological conditions such as diabetes, atherosclerosis, or aging, all of which are associated with alterations in the intracellular redox state [1, 2] . Chronic activation of platelets results in an increased risk of capillary plugging as well as in an increased systemic vascular tone. Thus, it is important to assess the influence of oxidants on platelet reactivity, as they may become a potential target for therapeutic strategies to prevent enhanced platelet activation [3] .
Aggregation is considerably influenced by the autocrine prostanoid thromboxane A 2 (TxA 2 ) [4, 5] . The key enzyme in the cascade of TxA 2 formation, which leads to platelet aggregation and thrombus formation, is prostaglandin endoperoxide H 2 synthase-1 (PGHS-1) also referred as cyclooxygenase-1 (COX-1), which can be eminently modulated by peroxides [6, 7] . Peroxides or peroxynitrite [8, 9] convert the resting PGHS-1 into its active form in which a ferric heme together with a neighboring tyrosine (Tyr)-residue are converted to a ferryl species and a Tyr-radical, respectively. The interaction of this Tyrradical with the substrate arachidonic acid yields an arachidonyl radical, which is capable of interacting with molecular oxygen to form 15-hydroperoxy-prostaglandin-9,11,-endoperoxide (PGG 2 ). In a second step, PGG 2 is reduced by the peroxidase activity of the enzyme to finally form the 15-hydroxy derivative PGH 2 [10, 11] . PGH 2 is the substrate for a variety of different terminal prostanoid synthases, among which thromboxane A 2 (TxA 2 ) synthase plays a crucial role in platelets [5] . The initiation and maintenance of the PGHS catalytic cycle by peroxides was termed "peroxide tone" [12] . Interestingly, the peroxide tone for the two PGHS isoenzymes was reported to be 21 nM for PGHS-1 but only 2 nM for PGHS-2 [13] . With some exceptions, inducible PGHS-2 is usually expressed under diverse pathological conditions, which are mostly associated with an increased formation of oxidants [14] . Unlike PGHS-2, PGHS-1 is constitutively expressed in both platelets and in numerous other cell types. Its considerably higher peroxide threshold can therefore be regarded as an effective biological regulatory mechanism to prevent uncontrolled prostanoid synthesis under resting conditions.
The key modulators of cellular redox regulation are nitric oxide ( · NO) and superoxide (   ·   O 2 -) as well as their derivatives [15, 16] . Both radicals can rapidly react with each other, leading to the formation of peroxynitrite (ONOO -) [17] . Peroxynitrite is mostly known to exhibit detrimental effects such as the initiation of lipid peroxidation, nitration of aromatic compounds, or oxidative modifications of sulfhydryl residues [18] [19] [20] . Although rightly considered as a highly reactive oxidant at high concentrations, endogenously formed peroxynitrite in the nanomolar range can be an important mediator of cellular redox regulation [15, 16] .
While the constitutively expressed endothelial NO-synthase (eNOS) is generally considered as the major NOS isoform in platelets [21] These effects need to be clearly separated from high nonphysiological (300-1000 μM) additions of ONOO -, where undirected protein oxidation and inactivation occur altering platelet aggregation [30] . We present evidence that endogenously formed peroxynitrite is a regulator of PGHS-1 activity and TxA 2 formation, capable of altering platelet aggregation. This is supported by the notions that antioxidants and polyphenols [34] [35] [36] [37] can influence TxA 2 and platelet aggregation [36] . The proposed mechanism could provide a molecular explanation for the clinically observed hyperreactivity of platelets in various pathophysiological conditions such as diabetes, arteriosclerosis or the aging process.
Materials and methods

Materials
Sin-1, the active metabolite of molsidomine, xanthine oxidase (buttermilk), and apocynin were purchased from Calbiochem (Darmstadt, Germany). Ascorbic acid, γ-tocopherol, glutathione (GSH), and hypoxanthine were from Sigma (St. Louis, MO, USA). SpermineNONOate was from Cayman Chemicals (Ann Arbor, MI, USA) and 14 Clabeled arachidonic acid was obtained from American Radiolabeled Chemicals (ARC) (St. Louis, MO, USA).
Preparation of platelets
Blood was collected from healthy volunteers between 20 and 30 years of age at the Herz-Zentrum Bodensee, Kreuzlingen. The Institutional Review Board of the Kanton Thurgau, Switzerland, approved the protocol for blood collection. Volunteers abstained from taking any NSAID for at least two weeks before venipuncture. Platelet rich plasma (PRP) was obtained by centrifugation of whole blood at 150 g for 15 min. Washed platelets were obtained according to the protocol of Boulos et al. [26] with minor modifications. To avoid contamination with lymphocytes and erythrocytes, at least 5 mm of the PRP fraction closest to the lymphocyte/erythrocyte fraction was discarded. To obtain plasma-free platelets, PRP was further centrifuged at 450 g for 15 min and resuspended in 5 mM Hepes-buffer, pH 7.0 containing 140 mM NaCl, 2 mM KCl, 14 mM NaHCO 3 , 5.5 mM glucose Fig. 1 . Activation of PGHS and aggregation by peroxynitrite. Platelet rich plasma was preincubated with hydrogen peroxide (H 2 O 2 , 1-100 μM) (A), Sin-1 (10-1000 μM) (B) for 20 min at 37°C under constant shaking (200 rpm). Aggregation was triggered after 2 min by addition of A23187 (2 µM). Treatment with authentic peroxynitrite (1-100 μM) (C) was performed under vigorous mixing and aggregation and PGHS-activity was measured after 2 min by addition of A23187 (2 µM). H 2 O 2 resulted in marginal stimulation (A) in response to A23187 (2 µM), whereas the peroxynitrite-generating compound Sin-1 (B) significantly elevated platelet PGHS turnover and aggregation. Relative steady-state concentrations of peroxynitrite over the time-course of the experiments released by Sin-1 under the conditions employed were in the nanomolar range. (C) Treatment of platelets with authentic peroxynitrite caused a concentration-dependent inhibition of platelet aggregation due to the formation of S-nitrosothiols with serum proteins and low molecular weight thiols as reported by Moro et al. [48] . Values are means ± SD (n =6) (⁎P b 0.05). 
Aggregometry
Aggregation of PRP was performed at 37°C in glass cuvettes (Probe and Go, Endingen, Germany) with constant stirring at 700 rpm in an Elvi 840 aggregometer from Logos (Milano, Italy). PRP was pretreated with the respective compounds for 20 min at 37°C under constant shaking (200 rpm). Shape change and aggregation were recorded. Using blood from the same donor, single sets of experiments were performed. Maximal obtainable A23187-induced changes in light transmission without addition of other compounds were defined as 100%.
PGHS activity
Activity of purified PGHS-1 from ram seminal vesicles and of intact platelets was detected as described previously [8] . Purified PGHS-1 from ram seminal vesicles was purchased from Cayman, Ann Arbor, MI. Contaminating peroxides were removed by addition of 5units glutathione (GSH)-peroxidase, 0.2 mM GSH, 325 units/100 µl catalase to the enzyme (10 units/100 µl), which was incubated at 37°C with 100 µM phenol and 0.1 µg/100 µl hematin in 0.1 mM Tris-HCl, pH 8.0. C-AA and 2 µM A23187 and terminated after 15 min by 1 ml ethyl acetate/citric acid (2 M) (30:1). After vigorous mixing of the phases for at least 1 min, the organic phase (0.9 ml) was extracted, evaporated to a residual volume of approximately 0.1 ml, spotted by glass capillaries onto silica TLC plates (Silica 60, Merck, Darmstadt, Germany) and subjected to chromatography with the mobile phase consisting of ethyl acetate: 2,2,4-trimethylpentane: acetic acid: water (110: 50: 20: 100). For detection and quantification, a PhosphorImager™ system from Molecular Dynamics (Sunnyvale, CA) was used. Quantification of purified PGHS-1 activity was performed by the detection of total PGHS metabolites. Platelet PGHS activity was determined by quantification of TxA 2 generation relative to unmetabolized 14 C-AA using ImageQuant™ software.
Platelet treatment with authentic peroxynitrite
Authentic peroxynitrite was synthesized according to the method by Beckman and Koppenol [17] , and the concentration was determined spectrophotometrically (ε 302 = 1670 M -1 cm -1 ). Controls were performed with decomposed peroxynitrite. All working solutions were prepared in 1 mM NaOH. Platelet rich plasma at 37°C was vigorously mixed with peroxynitrite. After 2 min platelets were subjected to aggregation and PGHS-activity measurements.
Detection of reactive oxygen species (ROS)
ROS formation was detected using the L-012-enhanced chemiluminescence (Wako Chemicals, Neuss, Germany) in a thermostated Sirius Luminometer from Berthold Detection Systems (Pforzheim, Germany) at intervals of 5 s. 200 µl of washed platelets (0.5⁎10 8 /ml) were preincubated with the respective reagents and 100 µM deferoxamine to prevent Fenton chemistry for 20 min at 37°C under constant shaking at 200 rpm. Before detection of chemiluminescence, L-012 (100 µM) was incubated for 3 min to allow equilibration before stimulation. A23187 (2 µM) was then added, and chemiluminescence was expressed as percent of relative light units (RLU). Alternatively, dihydrorhodamine 123 (DHR123) (5 μM) was added to platelets for 15 min in the dark following fluorescence detection (485 nm/538 nm).
· NO-Detection · NO release by platelets was detected with a · NO electrode (ami NO-700, Innovative Instruments, Quee Brooks Court, FL, USA). The electrode was calibrated every day with NaNO 2 standards in 0.1 M H 2 SO 4 containing 100 µM potassium iodide. For calibration of the instrument, the Δ-current between baseline and the peak after addition of NaNO 2 was determined.
Plasma-free platelets (0.5⁎10 8 /ml) were pretreated with apocynin, PEG-SOD, or L-NAME for 20 min at 37°C under constant shaking (200 rpm). A total volume of 400 µl was then transferred to a glass cuvette, and · NO release was detected under constant stirring at 700 rpm in an Elvi 840 aggregometer (Logos, Milano, Italy) following the addition of 2 µM A23187.
Preparation of peroxynitrite-treated lipid fractions of platelets
Microsomes obtained from human platelets by standard procedures were treated 3 times with 500 µM of authentic peroxynitrite. The membrane peroxide concentration in this solution was detected by the ferric thiocyanate assay. Briefly, 495 µl of 4.5 mM FeSO 4 in 0.2 M HCl and 495 µl of 3% KSCN in MeOH were mixed immediatedly before the addition of 10 µl sample. Absorbance was detected at 500 nm
).
Statistical analysis
All data were expressed as mean± SD of at least three independent experiments. Due to individual differences between different donors, single sets of experiments were performed with blood from the same preparation. One way ANOVA was used to determine the significance of differences. A probability value of p b 0.05 was considered statistically significant. 
Results
In this study, we used the Ca 2+ -ionophore A23187 as the stimulus of choice because it allows the Ca 2+ -dependent activation not only of phospholipase A 2 , but also of eNOS in platelets. Under such conditions, prostaglandin endoperoxide synthase-1 (PGHS-1) becomes the ratelimiting enzyme for TxA 2 synthesis and TxA 2 -dependent aggregation. A23187-induced aggregation was inhibited by roughly 70% with 100 µM indomethacin or aspirin, therefore suggesting that TxA 2 is one of the dominating mediators of platelet aggregation (not shown).
Sin [38] and Supplemental Material S1). While H 2 O 2 even in the micromolar range triggered PGHS activity and aggregation only moderately (Fig. 1A) peroxynitrite was stimulatory when present at only nanomolar concentrations (Fig.  1B) , an observation that implies that the potency of peroxynitrite is several orders of magnitude higher than that of H 2 O 2 . In contrast, after bolus additions of high concentrations of authentic peroxynitrite (Fig.  1C ) a reduction in PGHS-1 activity and platelet aggregation can be observed, suggesting that in addition to other proteins, PGHS becomes nitrated and inactivated. This has been observed for isolated PGHS [9] as well as in platelets [26] . Inhibition of the endogenous formation of peroxynitrite in activated platelets by the NADPH-oxidase complex assembly inhibitor apocynin, PEG-SOD, the NOS-inhibitor L-NAME, or uric acid, which besides · NO and hydroxyl radicals also efficiently scavenges peroxynitrite, in each case lowered PGHS activity and platelet aggregation in a concentration-dependent manner (Figs. 2 A-D) . These data support the concept that a major portion of the intracellular peroxide tone in platelets is provided by peroxynitrite. The activity of TxA 2 -synthase was not affected by the different treatments employed in this work as detected by the conversion of 14 C-PGH 2 into 14 C-TxA 2 (data not shown). TxA 2 released into the supernatant was measured as its stable hydration product TxB 2 (Supplemental Material S2) and qualitatively revealed similar results as obtained in platelet aggregation and PGHS activity.
Incubation of intact platelets with the peroxynitrite-donating compound Sin-1 could lead to the formation of various lipid oxidation products such as lipidhydroperoxides, nitrolipids or lipid alcohols that alternatively could influence PGHS activity by, for example, providing the peroxide tone via lipid hydroperoxides. However, treatment with increasing concentrations of ONOO -treated lipid fractions caused minimal effects on PGHS activity and aggregation, and therefore lipid oxidation products appear as rather unlikely to account for the effects observed with Sin-1 in this study (Fig. 3) . The luminol derivative L-012 and dihydrorhodamine 123 were used to estimate endogenous radical formation in activated platelets. L-012 demonstrated certain specificity for peroxynitrite, however it has to be mentioned that the detection of other radical species cannot be excluded. The inhibition of the L-012 chemiluminescence signal by uric acid, apocynin, or PEG-SOD but not by PEG-catalase strongly underscores the significance of endogenously formed peroxynitrite in A23187 activated platelets (Fig. 4) . To test the contribution of · NO and TxA 2 in aggregation, platelets were treated with the guanylyl cyclase inhibitor ODQ, thus eliminating the direct anti-aggregatory properties of · NO. ODQ only marginally increased platelet aggregation initiated by A23187 whereas the PGHS-inhibitor aspirin efficiently prevented platelet aggregation therefore supporting the role of pro-aggregatory TxA 2 (Supplement Material S3).
To exclude the involvement of the cellular redox milieu on the effects described here, isolated and purified PGHS-1 enzyme was obtained to directly determine the efficacy of peroxynitrite as a physiological activator. The peroxynitrite-generating compound Sin-1 caused nearly a doubling of PGHS-1 activity in a concentrationdependent manner (Fig. 5A) . To further highlight the role of peroxynitrite in eliciting PGHS-1 activity, the enzyme was incubated with 1 mM Sin-1 for full activation together with various concentrations of the anti-oxidants ascorbic acid or γ-tocopherol. In all cases, a concentration-dependent inhibition of PGHS-1 activity was observed (not shown increasing concentrations of peroxynitrite originating from the interaction of both radicals also yielded a concentration-dependent activation of PGHS-1 (Fig. 5B) . From previous kinetic calculations it was concluded that the combinations of Spermine-NONOate and XO used in Fig. 5 (Fig. 7A) , or PEG-SOD (Fig. 7B) 
Discussion
Concept of the "peroxide tone"
The activation of prostaglandin endoperoxide H 2 synthase (PGHS; COX) was summarized by the term "peroxide tone" [8, 39, 40] , which describes that for the initiation and maintenance of the PGHS catalytic cycle, a steady presence of peroxides or peroxynitrite [9] is required. This unique property of the PGHS isoenzymes originates from their radical-based catalytic mechanism. It ultimately leads to the formation of a tyrosyl radical at the active site, which is necessary to activate the substrate arachidonic acid. Due to the reductive environment in a cell, this radical-based mechanism is continuously interrupted and requires a permanent reactivation by peroxides. Therefore the catalytic cycle of PGHS is of transient nature and dictated by intracellular peroxide levels.
The peroxide tone for the inducible PGHS-2 was found to be 10-fold lower (2 nM) than that for the constitutive PGHS-1 (21 nM) [13] . Since PGHS-1 is expressed in most mammalian tissues, the higher peroxide tone for PGHS-1 could be considered an efficient means to prevent uncontrolled prostanoid formation under resting conditions. This is illustrated in human platelets, which constitutively express PGHS-1 and thromboxane A 2 (TxA 2 )-synthase. TxA 2 is a potent autocrine inducer of platelet aggregation and plays a vital role in rapid cessation of bleeding [41, 42] . Under physiological conditions however, uncontrolled formation of TxA 2 has to be strictly prevented in order to avoid thrombus formation in the vascular system (Fig. 8) .
The data presented demonstrate and confirm previous literature reports [9, 43] that peroxynitrite in the low nanomolar range acts as a potent endogenous activator of PGHS-1, which triggers TxA 2 formation and aggregation in human platelets. Several reports indicate a direct impact of peroxynitrite on platelet function [29, 33] . In most of these studies, authentic peroxynitrite in the upper micromolar range was used and led to protein nitration and reduced TxA 2 generation. Such high concentrations, however, are far above the levels of endogenously formed reactive oxygen species. Furthermore, due to its short half-life time (t 1/2 ≈1 s), application of authentic peroxynitrite creates a very rapid peak and decay, which is not representative for the situation in vivo. In contrast to these reports [26, 29, 30, 44] , we used the peroxynitrite-generating compound Sin-1. Under the conditions applied in this work, 1 mM Sin-1 approximates relative steady-state peroxynitrite concentrations of about 100-200 nM over the time-course of the experiments. The proportion of the Sin-1-derived peroxynitrite reaching the target PGHS is likely to be considerably diminished compared to endogenously formed peroxynitrite on account to the closer proximity of endogenous sources to the target. Therefore, the peroxynitrite concentrations experimentally generated actually represent higher levels (peroxide tone of PGHS-1 ≈ 21 nM) of peroxinitrite than the situation in vivo in order to saturate the peroxide tone. · NO is well known for its role as anti-coagulant by the established increase in intracellular cGMP levels [45] . However, when A23187 was used as a stimulus, a modest proportion of the endogenously formed · NO by platelet eNOS prevented aggregation, as proven by incubation with the guanylyl cyclase inhibitor ODQ. With respect to its antiaggregatory property, NOS inhibitors should promote aggregation rather than inhibit it. Radomski et al. [46] demonstrated that a 3-minute preincubaion with L-NMMA resulted in an increase in aggregation of stimulated platelets. We could successfully reproduce these findings (Supplemental Material S4). Nevertheless, some evidence exists suggesting that the anti-aggregatory role of platelet-derived · NO was overestimated in the past. Freedman and coworkers demonstrated that · NO has only moderate inhibitory properties on initial platelet activation but had profound impact on additional platelet recruitment to an existing thrombus [47] . To block the endogenous peroxynitriteprovided peroxide tone, a prolonged incubation time (≥20 min) of either L-NAME or L-NMMA was necessary. Then, the TxA 2 -mediated effects dominated over those directly evoked by endogenous · NO (Supplemental Material S4).
A second mechanism proposed by Moro et al. [29, 48, 49] contended that if peroxynitrite is added as a bolus at low micromolar concentrations to platelet rich plasma, plasma proteins and low molecular weight thiols might be converted into S-nitrosothiols [50] . These can liberate free · NO and prevent platelet aggregation via the classical · NO/ cGMP-pathway. We could successfully reproduce these effects as shown in Fig. 1C . Other groups used washed platelets and treated them with peroxynitrite, which at low concentrations caused an increase in aggregation and TxA 2 release, whereas high concentrations resulted in protein oxidation and nitration [9, 26, 30, 44] that inhibited PGHS [9, 26] and reduced aggregation [26] . Because Sin-1 generated nanomolar fluxes of peroxynitrite and platelets may be permeable for the compound, the S-nitrosothiol formation in plasma may play a minor role. In contrast to our findings, there are older reports that claim Sin-1 as an · NO-donor that inhibits platelet aggregation [51] [52] [53] in a cGMPdependent way. As shown in Fig. S1 , the fluxes of Sin-1-generated peroxynitrite must stabilize over the first 5 min due to the complex chemistry of Sin-1 decomposition [50] and are therefore "only relatively steady state." In the first few minutes Sin-1 may release relatively more -are generated in an equimolar ratio. An excess of either radical significantly decreases the levels of reactive peroxynitrite [54] and therefore reduces the peroxide tone and PGHS activity [8] . In accordance with these previous observations, the addition of · NO in excess of peroxynitrite significantly reduced PGHS activity in intact platelets. It has to be highlighted that the ratio between endogenously formed NO was reported to attenuate PGHS activity by a direct reaction with the active site tyrosyl radical of the enzyme [43, 55, 56] , nonphysiological concentrations of at least 1-2 mM of free · NO were required for this interaction, which renders this mechanism as very unlikely to occur in biological systems [57] .
A second pathway to explain how · NO could attenuate platelet aggregation is the recently discovered · NO-dependent S-glutathiolation and activation of the Ca 2+ -pump SERCA, which lowers the levels of [Ca 2+ ] i [58] . Nevertheless, in the current study, effects of · NO on SERCA activity can be neglected, since the potent Ca 2+ -ionophore A23187 was used to obtain maximal activation of the eicosanoid-signaling cascade. We have chosen the Ca 2+ -ionophore A23187 at a relatively high concentration (2 µM) to cause maximal platelet activation. With respect to the questions addressed in this work, an increase of [Ca 2+ ] i was mainly required for the PLA 2 -catalyzed release of AA and the activation of eNOS. By comparing the effects of complexation and re-addition of .
Can other peroxides provide the peroxide tone?
Several publications previously indicated an involvement of H 2 O 2 on TxA 2 production and platelet aggregation [25, 27] . In these reports, activation at low concentrations of H 2 O 2 was followed by an inhibition at higher concentrations [27] . Although H 2 O 2 can undoubtedly be involved in generating the intracellular peroxide tone, the fact that peroxynitrite is about 500-1000 times more potent than H 2 O 2 in activating PGHS in platelets, makes peroxynitrite the more likely endogenously relevant candidate. Furthermore, application of PEGcatalase revealed no significant impact on platelet aggregation, PGHS activity, or TxB 2 formation under the experimental conditions employed in this work (Supplemental Material S5). The incubation of platelets with the peroxynitrite-donor Sin-1 could alternatively lead to the formation of lipid oxidation products such as nitrolipids, lipid hydroperoxides, or lipid alcohols, which in turn could serve as modulators of PGHS-activity. Human platelet membrane fractions were therefore treated with peroxynitrite. Incubation of intact platelets with these lipid fractions had no effect on PGHS activity and aggregation. From the observations made in this work in human platelets as well as in other cell types like vascular endothelial and smooth muscle cells [8, 34, 40, 43, 59 ], peroxynitrite appears to be one of the most potent endogenously formed regulators of PGHS activity and prostanoid synthesis in mammalian cells.
Interference of antioxidants with the peroxide tone
The concept of the peroxynitrite-mediated activation of PGHS-1 and ultimately TxA 2 synthesis by platelets also gives an explanation for several previous studies on the influence of antioxidants on platelet aggregation. Uric acid, vitamin C, and vitamin E, in particular γ-tocopherol, could efficiently scavenge peroxynitrite and attenuate platelet aggregation. For vitamin E, PGHS-independent effects on platelet aggregation were shown [60] . However, we could not observe additional effects of γ-tocopherol on platelet aggregation after inhibition of TxA 2 synthesis by aspirin thus strongly suggesting a direct influence of antioxidants on the cellular peroxide tone. The concept of antioxidants as scavengers of peroxynitrite and their impact on PGHS activity [35, 36] is not only limited to the situation in platelets but was, for example, also demonstrated in macrophages from old mice [34] and can certainly be considered as a general mechanism taking place in nearly all cell types [8, 9, 26, 40, 43, 59] .
Conclusions
The vascular system can be regarded as a perfect example of a biological yin-yang system in which anti-aggregatory PGI 2 from the endothelium and pro-aggregatory TxA 2 from platelets represent a well-balanced system of vasoactive eicosanoids. Under physiological conditions, a significant portion of PGI 2 is formed in a PGHS-2-dependent manner, although the precise anatomic origin of PGI 2 is so far only poorly defined [61] . Due to the 10-fold lower requirement for peroxides to activate PGHS-2, the "peroxide tone" would rather favor the formation of anti-aggregatory PGI 2 under normal conditions, whereas the formation of TxA 2 would be suppressed. However, pathophysiological conditions are associated with an increased oxidant formation. Such circumstances would favor the inactivation of PGI 2 -synthase by nitration in the endothelium and in parallel would enhance the formation of TxA 2 by platelets [20] . With the concept of peroxynitrite as an activator of PGHS-1-dependent TxA 2 formation and aggregation, previous clinical observations made with different antioxidants might now be explained on the molecular level. A pharmacological modification of the "net effect" of peroxynitrite in the vasculature may eventually become a novel strategy to combat chronic pathophysiological situations like diabetes, atherosclerosis or aging.
